A narrative review of the therapeutic and remedial prospects of cannabidiol with emphasis on neurological and neuropsychiatric disorders | Journal of Cannabis Research
Abame MA, He Y, Wu S, Xie Z, Zhang J, Gong X, Wu C, Shen J. Chronic administration of synthetic cannabidiol induces antidepressant effects involving modulation of serotonin and noradrenaline levels in the hippocampus. Neurosci Lett. 2021;744:135594.
Abichabki N, Zacharias LV, Moreira NC, Bellissimo-Rodrigues F, Moreira FL, Benzi JR, Ogasawara T, Ferreira JC, Ribeiro CM, Pavan FR. Potential cannabidiol (CBD) repurposing as antibacterial and promising therapy of CBD plus polymyxin B (PB) against PB-resistant gram-negative bacilli. Sci Reports. 2022;12:1–15.
Abichabki, N., Zacharias, L.V., Moreira, N.C., Bellissimo-Rodrigues, F., Moreira, F.L., Benzi, J.R., Ogasawara, T.M., Ferreira, J.C., Pereira, L.R., Braga, G.Ú. Cannabidiol (CBD) repurposing as antibacterial: Promising therapy of CBD plus polymyxin B against superbugs. bioRxiv.2021 https://doi.org/10.1101/2021.04.12.439341.
Alvarez FJ, Lafuente H, Carmen Rey-Santano M, Mielgo VE, Gastiasoro E, Rueda M, Pertwee RG, Castillo AI, Romero J, Martinez-Orgado J. Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets. Ped Res. 2008;64:653–8.
Anil SM, Shalev N, Vinayaka AC, Nadarajan S, Namdar D, Belausov E, Shoval I, Mani KA, Mechrez G, Koltai H. Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages. Sci Reports. 2021;11:1–14.
Aswad M, Hamza H, Pechkovsky A, Zikrach A, Popov T, Zohar Y, Shahar E, Louria-Hayon I. High-CBD extract (CBD-X) downregulates cytokine storm systemically and locally in inflamed lungs. Front Immunol. 2022;13:2252.
Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Antioxidative and anti-inflammatory properties of cannabidiol. Anti. 2019;9:21.
Autry AE, Monteggia LM. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev. 2012;64:238–58.
Aziz A-I, Nguyen LC, Oumeslakht L, Bensussan A, Ben Mkaddem S. Cannabinoids as immune system modulators: cannabidiol potential therapeutic approaches and limitations. Cannabis and Cannabinoid Research. 2022;8:254.
Aziz A-I, Nguyen LC, Oumeslakht L, Bensussan A, Ben Mkaddem S. Cannabinoids as immune system modulators: cannabidiol potential therapeutic approaches and limitations. Cannabis Cannabinoid Res. 2022;8(2):254–69. https://doi.org/10.1089/can.2022.0133.
Bartschi JG, Greenwood L-M, Montgomery A, Dortants L, Weston-Green K, Huang X-F, Pai N, Potter J, Schira MM, Croft R. Cannabidiol as a treatment for neurobiological, behavioral, and psychological symptoms in early-stage dementia: a double-blind, placebo-controlled clinical trial protocol. Cannabis Cannabinoid Res. 2023;8:348–59.
Basavarajappa BS. Critical enzymes involved in endocannabinoid metabolism. Protein Pept Lett. 2007;14:237–46.
Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci. 2015;11:1164–78.
Berger M, Li E, Amminger GP. Treatment of social anxiety disorder and attenuated psychotic symptoms with cannabidiol. BMJ Case Reports CP. 2020;13:e235307.
Bhunia S, Kolishetti N, Arias AY, Vashist A, Nair M. Cannabidiol for neurodegenerative disorders: A comprehensive review. Front Pharmacol. 2022;13:989717.
Biernacki M, Brzóska MM, Markowska A, Gałażyn-Sidorczuk M, Cylwik B, Gęgotek A, Skrzydlewska E. Oxidative stress and its consequences in the blood of rats irradiated with UV: protective effect of cannabidiol. Anti. 2021;10:821.
Bisogno T, Hanuš L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, Di Marzo V. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol. 2001;134:845–52.
Blaskovich MA, Kavanagh AM, Elliott AG, Zhang B, Ramu S, Amado M, Lowe GJ, Hinton AO, Pham DMT, Zuegg J. The antimicrobial potential of cannabidiol. Commun Biol. 2021;4:1–18.
Borea PA, Gessi S, Merighi S, Vincenzi F, Varani K. Pathological overproduction: the bad side of adenosine. Br J Pharmacol. 2017;174:1945–60.
Britch SC, Babalonis S, Walsh SL. Cannabidiol: pharmacology and therapeutic targets. Psychopharmacology. 2021;238:9–28.
Cabrera CLR, Keir-Rudman S, Horniman N, Clarkson N, Page C. The anti-inflammatory effects of cannabidiol and cannabigerol alone, and in combination. Pulm Pharmacol Ther. 2021;69:102047.
Carbonell WS, Murase S-I, Horwitz AF, Mandell JW. Migration of perilesional microglia after focal brain injury and modulation by CC chemokine receptor 5: an in situ time-lapse confocal imaging study. J Neurosci. 2005;25:7040–7.
Carlini E, Leite J, Tannhauser M, Berardi A. Cannabidiol and Cannabis sativa extract protect mice and rats against convulsive agents. J Pharm Pharmacol. 1973;25:664–5.
Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci. 2006;103:7895–900.
Cassol-Jr OJ, Comim CM, Silva BR, Hermani FV, Constantino LS, Felisberto F, Petronilho F, Hallak JEC, De Martinis BS, Zuardi AW. Treatment with cannabidiol reverses oxidative stress parameters, cognitive impairment and mortality in rats submitted to sepsis by cecal ligation and puncture. Brain Res. 2010;1348:128–38.
Cenova A, Nestorovska M, Crcarevska MS, Mihailova L, Shalabalija D, Dodov MG. Evaluation of antioxidant properties of herbal mixture and CBD oil for the treatment of chronic wound. Macedonian Pharm Bull. 2022;68:557–8.
Chagas MH, Eckeli A, Zuardi AW, Pena-Pereira MA, Sobreira-Neto MA, Sobreira E, Camilo M, Bergamaschi M, Schenck C, Hallak JEC. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series. J Clin Phar Ther. 2014;39:564–6.
Chayasirisobhon S. Mechanisms of action and Pharmacokinetics of Cannabis. The Permanente Journal. 2020;25:1–3.
Chen KA, Farrar M, Cardamone M, Gill D, Smith R, Cowell CT, Truong L, Lawson JA. Cannabidiol for treating drug-resistant epilepsy in children: the New South Wales experience. Med J Aust. 2018;209:217–21.
Chesworth R, Cheng D, Staub C, Karl T. Effect of long-term cannabidiol on learning and anxiety in a female Alzheimer’s disease mouse model. Front Pharmacol. 2022;13:931384.
Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, Kennedy K, Schram K. Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol Biochem Behav. 1991;40:701–8.
Crippa JAS, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran FL, Martin-Santos R, Simões MV, Bhattacharyya S, Fusar-Poli P, Atakan Z. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharm. 2011;25:121–30.
Cuñetti L, Manzo L, Peyraube R, Arnaiz J, Curi L, Orihuela S. Chronic pain treatment with cannabidiol in kidney transplant patients in Uruguay. Transplant Proc. 2018;50(2):461–4.
da Silva VK, de Freitas BS, Garcia RCL, Monteiro RT, Hallak JE, Zuardi AW, Crippa JAS, Schröder N. Antiapoptotic effects of cannabidiol in an experimental model of cognitive decline induced by brain iron overload. Transl Psychiatry. 2018;8:1–8.
Davidson, E., 2022 https://clinicaltrials.gov/ct2/show/NCT03877991. Bioequivalence Assessment of Cannabidiol (CBD) Administrated in Oral Formulations.
de Almeida CM, Brito MM, Bosaipo NB, Pimentel AV, Tumas V, Zuardi AW, Crippa JA, Hallak JE, Eckeli AL. Cannabidiol for rapid eye movement sleep behavior disorder. Mov Disord. 2021;36:1711–5.
De Petrocellis L, Ligresti A, Moriello AS, Allarà M, Bisogno T, Petrosino S, Stott CG, Di Marzo V. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 2011;163:1479–94.
Della Rocca G, Paoletti F, Conti MB, Galarini R, Chiaradia E, Sforna M, Dall’Aglio C, Polisca A, Di Salvo A. Pharmacokinetics of cannabidiol following single oral and oral transmucosal administration in dogs. Front Vet Sci. 2022;9:1104152.
Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. New Engl J Med. 2017;376:2011–20.
Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, Miller I, Flamini R, Wilfong A, Filloux F. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15:270–8.
Devinsky O, Nabbout R, Miller I, Laux L, Zolnowska M, Wright S, Roberts C. Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial. Epilepsia. 2019;60:294–302.
Devinsky O, Verducci C, Thiele EA, Laux LC, Patel AD, Filloux F, Szaflarski JP, Wilfong A, Clark GD, Park YD. Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Epilepsy Behav. 2018;86:131–7.
di Giacomo V, Chiavaroli A, Orlando G, Cataldi A, Rapino M, Di Valerio V, Leone S, Brunetti L, Menghini L, Recinella L. Neuroprotective and neuromodulatory effects induced by cannabidiol and cannabigerol in rat Hypo-E22 cells and isolated hypothalamus. Anti. 2020;9:71.
Ekiner SA, Gęgotek A, Skrzydlewska E. The molecular activity of cannabidiol in the regulation of Nrf2 system interacting with NF-κB pathway under oxidative stress. Redox Biol. 2022;57:102489.
ElBatsh MM, Assareh N, Marsden CA, Kendall DA. Anxiogenic-like effects of chronic cannabidiol administration in rats. Psychopharmacology. 2012;221:239–47.
Elms L, Shannon S, Hughes S, Lewis N. Cannabidiol in the treatment of post-traumatic stress disorder: a case series. J Altern Complement Med. 2019;25:392–7.
ElSohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 2005;78:539–48.
England T, O’Sullivan S. Protective effects of Cannabidivarin and Cannabigerol on cells of the blood-brain barrier under ischemic conditions. Cannabis Cannabinoid Res. 2021;6:315–26.
Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, Stone JM, Reichenberg A, Brenneisen R, Holt D. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol. 2013;27:19–27.
Fagherazzi EV, Garcia VA, Maurmann N, Bervanger T, Halmenschlager LH, Busato SB, Hallak JE, Zuardi AW, Crippa JA, Schröder N. Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders. Psychopharmacology. 2012;219:1133–40.
Feoktistov I, Biaggioni I. Role of adenosine A2B receptors in inflammation. Adv Pharmacol. 2011;61:115–44.
Fernández-Ruiz J, Sagredo O, Pazos MR, García C, Pertwee R, Mechoulam R, Martínez-Orgado J. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol. 2013;75:323–33.
Figler RA, Wang G, Srinivasan S, Jung DY, Zhang Z, Pankow JS, Ravid K, Fredholm B, Hedrick CC, Rich SS. Links between insulin resistance, adenosine A2B receptors, and inflammatory markers in mice and humans. Diabetes. 2011;60:669–79.
Fu X, Xu S, Li Z, Chen K, Fan H, Wang Y, Xie Z, Kou L, Zhang S. Enhanced intramuscular bioavailability of Cannabidiol using nanocrystals: formulation, in vitro appraisal, and pharmacokinetics. AAPS PharmSciTech. 2022;23:85.
García-Arencibia M, González S, de Lago E, Ramos JA, Mechoulam R, Fernández-Ruiz J. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson’s disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res. 2007;1134:162–70.
Ghit A, Assal D, Al-Shami AS, Hussein DEE. GABAA receptors: structure, function, pharmacology, and related disorders. J Genet Engine Biotechnol. 2021;19:1–15.
Gildea L, Ayariga JA, Ajayi OS, Xu J, Villafane R, Samuel-Foo M. Cannabis sativa CBD extract shows promising antibacterial activity against Salmonella typhimurium and S. Newington. Molecules. 2022;27:2669.
Giuliano C. Neuroprotective and symptomatic effects of Cannabidiol in an animal model of Parkinson’s disease. Int J Mol Sci. 2021;22:8920.
Giuliano C, Francavilla M, Ongari G, Petese A, Ghezzi C, Rossini N, Blandini F, Cerri S. Neuroprotective and symptomatic effects of cannabidiol in an animal model of Parkinson’s disease. Int J Mol Sci. 2021;22:8920.
Gu Z, Singh S, Niyogi RG, Lamont GJ, Wang H, Lamont RJ, Scott DA. Marijuana-derived cannabinoids trigger a CB2/PI3K axis of suppression of the innate response to oral pathogens. Front Immunol. 2019;10:2288.
Hammell D, Zhang L, Ma F, Abshire S, McIlwrath S, Stinchcomb A, Westlund K. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. Eur J Pain. 2016;20:936–48.
Hampson A, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (−) Δ9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci. 1998;95:8268–73.
Han X, Song X, Song D, Xie G, Guo H, Wu N, Li J. Comparison between cannabidiol and sertraline for the modulation of post-traumatic stress disorder-like behaviors and fear memory in mice. Psychopharmacology. 2022;239:1605–20.
Hao E, Mukhopadhyay P, Cao Z, Erdélyi K, Holovac E, Liaudet L, Lee W-S, Haskó G, Mechoulam R, Pacher P. Cannabidiol protects against doxorubicin-induced cardiomyopathy by modulating mitochondrial function and biogenesis. Mol Med. 2015;21:38–45.
Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. 2013;16:821–47.
Heineman JT, Forster GL, Stephens KL, Cottler PS, Timko MP, DeGeorge BR Jr. A randomized controlled trial of topical cannabidiol for the treatment of thumb basal joint arthritis. J Hand Surg. 2022;47:611–20.
Hermush V, Ore L, Stern N, Mizrahi N, Fried M, Krivoshey M, Staghon E, Lederman VE, Bar-Lev Schleider L. Effects of rich cannabidiol oil on behavioral disturbances in patients with dementia: a placebo controlled randomized clinical trial. Front Med. 2022;9:951889.
Hilaire G, Voituron N, Menuet C, Ichiyama RM, Subramanian HH, Dutschmann M. The role of serotonin in respiratory function and dysfunction. Respir Physiol Neurobiol. 2010;174:76–88.
Hosseini A, McLachlan AJ, Lickliter JD. A phase I trial of the safety, tolerability and pharmacokinetics of cannabidiol administered as single-dose oil solution and single and multiple doses of a sublingual wafer in healthy volunteers. Br J Clin Pharmacol. 2021;87:2070–7.
Hu X, Li J, Fu M, Zhao X, Wang W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6:402.
Hunter D, Oldfield G, Tich N, Messenheimer J, Sebree T. Synthetic transdermal cannabidiol for the treatment of knee pain due to osteoarthritis. OsCar. 2018;26:S26.
Hurd YL, Spriggs S, Alishayev J, Winkel G, Gurgov K, Kudrich C, Oprescu AM, Salsitz E. Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial. Am J Psychiatry. 2019;176:911–22.
Jean‐Gilles L, Braitch M, Latif ML, Aram J, Fahey AJ, Edwards LJ, et al. Effects of pro‐inflammatory cytokines on cannabinoid CB 1 and CB 2 receptors in immune cells. Acta Physiologica. 2015;214(1):63–74.
Jenny M, Schröcksnadel S, Überall F, Fuchs D. The potential role of cannabinoids in modulating serotonergic signaling by their influence on tryptophan metabolism. Pharmaceuticals. 2010;3(8):2647–60.
Jiang R, Yamaori S, Takeda S, Yamamoto I, Watanabe K. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci. 2011;89:165–70.
Jones PG, Falvello L, Kennard O, Sheldrick G, Mechoulam R. Cannabidiol. Acta Crystallogr Sect b: Struct Crystallogr Cryst Chem. 1977;33:3211–4.
Juan CA, Pérez de la Lastra JM, Plou FJ, Pérez-Lebeña E. The chemistry of reactive oxygen species (ROS) revisited: outlining their role in biological macromolecules (DNA, lipids and proteins) and induced pathologies. Int J Mol Sci. 2021;22:4642.
Jung YJ, Tweedie D, Scerba MT, Greig NH. Neuroinflammation as a factor of neurodegenerative disease: thalidomide analogs as treatments. Front Cell Dev Biol. 2019;7:313.
Kanova M, Kohout P. Serotonin—Its synthesis and roles in the healthy and the critically ill. Int J Mol Sci. 2021;22:4837.
Kaplan JS, Stella N, Catterall WA, Westenbroek RE. Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome. Proc Natl Acad Sci. 2017;114:11229–34.
Khaksar S, Bigdeli M, Samiee A, Shirazi-Zand Z. Antioxidant and anti-apoptotic effects of cannabidiol in model of ischemic stroke in rats. Brain Res Bull. 2022;180:118–30.
Kim YS, Joh TH. Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson’s disease. Exp Mol Med. 2006;38:333–47.
Kochen S, Villanueva M, Bayarres L, Daza-Restrepo A, Martinez SG, Oddo S. Cannabidiol as an adjuvant treatment in adults with drug-resistant focal epilepsy. Epilepsy Behav. 2023;144:109210.
Kosgodage US, Matewele P, Awamaria B, Kraev I, Warde P, Mastroianni G, Nunn AV, Guy GW, Bell JD, Inal JM. Cannabidiol is a novel modulator of bacterial membrane vesicles. Front Cell Infect Microbiol. 2019;9:324.
Kozela E, Juknat A, Kaushansky N, Rimmerman N, Ben-Nun A, Vogel Z. Cannabinoids decrease the Th17 inflammatory autoimmune phenotype. J Neuroimmune Pharmacol. 2013;8:1265–76.
Laprairie R, Bagher A, Kelly M, Denovan-Wright E. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015;172:4790–805.
Laun AS, Shrader SH, Brown KJ, Song Z-H. GPR3, GPR6, and GPR12 as novel molecular targets: their biological functions and interaction with cannabidiol. Acta Pharmacol Sin. 2019;40:300–8.
Lees R, Hines LA, Hindocha C, Baio G, Shaban ND, Stothart G, Mofeez A, Morgan CJ, Curran HV, Freeman TP. Effect of four-week cannabidiol treatment on cognitive function: secondary outcomes from a randomised clinical trial for the treatment of cannabis use disorder. Psychopharmacology. 2023;240:337–46.
Leweke F, Piomelli D, Pahlisch F, Muhl D, Gerth C, Hoyer C, Klosterkötter J, Hellmich M, Koethe D. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2:e94–e94.
Lima Giacobbo B, Doorduin J, Klein HC, Dierckx RA, Bromberg E, de Vries EF. Brain-derived neurotrophic factor in brain disorders: focus on neuroinflammation. Mol Neurobiol. 2019;56:3295–312.
Lin C-C, Huang T-L. Brain-derived neurotrophic factor and mental disorders. Biomed J. 2020;43:134–42.
Linares IM, Zuardi AW, Pereira LC, Queiroz RH, Mechoulam R, Guimarães FS, Crippa JA. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Brazilian J Psychiatry. 2018;41:9–14.
Linge R, Jiménez-Sánchez L, Campa L, Pilar-Cuéllar F, Vidal R, Pazos A, Adell A, Díaz Á. Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors. Neuropharmacology. 2016;103:16–26.
Liput DJ, Hammell DC, Stinchcomb AL, Nixon K. Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder. Pharmacol Biochem Behav. 2013;111:120–7.
Lodzki M, Godin B, Rakou L, Mechoulam R, Gallily R, Touitou E. Cannabidiol—transdermal delivery and anti-inflammatory effect in a murine model. J Control Release. 2003;93:377–87.
Lowin T, Tingting R, Zurmahr J, Classen T, Schneider M, Pongratz G. Cannabidiol (CBD): A killer for inflammatory rheumatoid arthritis synovial fibroblasts. Cell Death Dis. 2020;11:1–11.
Lu H-C, Mackie K. An introduction to the endogenous cannabinoid system. Biol Psychiat. 2016;79:516–25.
Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018;84:2477–82.
Machado Bergamaschi M, Helena Costa Queiroz R, Waldo Zuardi A, Crippa AS. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Safety. 2011;6:237–49.
Magen I, Avraham Y, Ackerman Z, Vorobiev L, Mechoulam R, Berry EM. Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation. J Hepatol. 2009;51:528–34.
Mammana S, Cavalli E, Gugliandolo A, Silvestro S, Pollastro F, Bramanti P, Mazzon E. Could the combination of two non-psychotropic cannabinoids counteract neuroinflammation? Effectiveness of cannabidiol associated with cannabigerol. Medicina. 2019;55:747.
Mariga A, Mitre M, Chao MV. Consequences of brain-derived neurotrophic factor withdrawal in CNS neurons and implications in disease. Neurobiol Dis. 2017;97:73–9.
Martín-Moreno AM, Reigada D, Ramírez BG, Mechoulam R, Innamorato N, Cuadrado A, de Ceballos ML. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer’s disease. Mol Pharmacol. 2011;79:964–73.
Martin EL, Strickland JC, Schlienz NJ, Munson J, Jackson H, Bonn-Miller MO, Vandrey R. Antidepressant and anxiolytic effects of medicinal cannabis use in an observational trial. Front Psych. 2021;12:1554.
Martínez-Orgado J, Villa M, Del Pozo A. Cannabidiol for the treatment of neonatal hypoxic-ischemic brain injury. Front Pharmacol. 2021;11:584533.
Massi P, Valenti M, Vaccani A, Gasperi V, Perletti G, Marras E, Fezza F, Maccarrone M, Parolaro D. 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. J Neurochem. 2008;104:1091–100.
Matias I, Gonthier M-P, Orlando P, Martiadis V, De Petrocellis L, Cervino C, Petrosino S, Hoareau L, Festy F, Pasquali R. Regulation, function, and dysregulation of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab. 2006;91:3171–80.
McAllister SD, Murase R, Christian RT, Lau D, Zielinski AJ, Allison J, Almanza C, Pakdel A, Lee J, Limbad C. Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat. 2011;129:37–47.
McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, Taylor A, Wright S. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry. 2018;175:225–31.
Mechoulam R, Hanuš L. Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chem Phys Lipid. 2002;121:35–43.
Meissner, H., Cascella, M., 2022 https://www.ncbi.nlm.nih.gov/books/NBK556048/
Misri S, Kaul K, Mishra S, Charan M, Verma AK, Barr MP, Ahirwar DK, Ganju RK. Cannabidiol inhibits tumorigenesis in cisplatin-resistant non-small cell lung cancer via TRPV2. Cancers (basel). 2022;14:1181.
Mohammed N, Ceprian M, Jimenez L, Ruth Pazos M, Martínez-Orgado J. Neuroprotective effects of cannabidiol in hypoxic ischemic insult. The therapeutic window in newborn mice. CNS Neurol Disord-Drug Targets. 2017;16:102–8 (Formerly Current Drug Targets-CNS & Neurological Disorders).
Morgan CJ, Das RK, Joye A, Curran HV, Kamboj SK. Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav. 2013;38:2433–6.
Muhammad F, Liu Y, Wang N, Zhao L, Zhou Y, Yang H, Li H. Neuroprotective effects of cannabidiol on dopaminergic neurodegeneration and α-synuclein accumulation in C. elegans models of Parkinson’s disease. Neurotoxicology. 2022;93:128–39.
Muñoz-Castañeda JR, Montilla P, Padillo FJ, Bujalance I, Muñoz MC, Muntané J, Túnez I. Role of serotonin in cerebral oxidative stress in rats. Acta Neurobiol Exp. 2006;66:1–6.
Murillo-Rodríguez E, Millán-Aldaco D, Palomero-Rivero M, Mechoulam R, Drucker-Colín R. Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats. FEBS Lett. 2006;580:4337–45.
Oláh A, Tóth BI, Borbíró I, Sugawara K, Szöllõsi AG, Czifra G, Pál B, Ambrus L, Kloepper J, Camera E. Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. J Clin Investig. 2014;124:3713–24.
Pan H, Mukhopadhyay P, Rajesh M, Patel V, Mukhopadhyay B, Gao B, Haskó G, Pacher P. Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death. J Pharmacol Exp Ther. 2009;328:708–14.
Pandolfo P, Silveirinha V, dos Santos-Rodrigues A, Venance L, Ledent C, Takahashi RN, Cunha RA, Köfalvi A. Cannabinoids inhibit the synaptic uptake of adenosine and dopamine in the rat and mouse striatum. Eur J Pharmacol. 2011;655:38–45.
Patra PH, Barker-Haliski M, White HS, Whalley BJ, Glyn S, Sandhu H, Jones N, Bazelot M, Williams CM, McNeish AJ. Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models. Epilepsia. 2019;60:303–14.
Peng J, Fan M, An C, Ni F, Huang W, Luo J. A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD). Basic Clin Pharmacol Toxicol. 2022;130:439–56.
Peres FF, Diana MC, Levin R, Suiama MA, Almeida V, Vendramini AM, Santos CM, Zuardi AW, Hallak JE, Crippa JA. Cannabidiol administered during peri-adolescence prevents behavioral abnormalities in an animal model of schizophrenia. Front Pharmacol. 2018;9:901.
Peyravian N, Deo S, Daunert S, Jimenez JJ. Cannabidiol as a novel therapeutic for immune modulation. ImmunoTargets Ther. 2020a;9:131.
Pokorski I, Clement N, Phung N, Weltman M, Fu S, Copeland J. Cannabidiol in the management of in-patient cannabis withdrawal: clinical case series. Future Neurol. 2017;12:133–40.
Porcari GS, Fu C, Doll ED, Carter EG, Carson RP. Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center. Epilepsy Behav. 2018;80:240–6.
Porter B, Marie BS, Milavetz G, Herr K. Cannabidiol (CBD) use by older adults for acute and chronic pain. J Gerontol Nurs. 2021;47:6–15.
Privitera M, Bhathal H, Wong M, Cross JH, Wirrell E, Marsh ED, Mazurkiewicz-Beldzinska M, Villanueva V, Checketts D, Knappertz V. Time to onset of cannabidiol (CBD) treatment effect in Lennox-Gastaut syndrome: Analysis from two randomized controlled trials. Epilepsia. 2021;62:1130–40.
Rajesh M, Mukhopadhyay P, Bátkai S, Patel V, Saito K, Matsumoto S, Kashiwaya Y, Horváth B, Mukhopadhyay B, Becker L. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol. 2010;56:2115–25.
Ramer R, Merkord J, Rohde H, Hinz B. Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1. Biochem Pharmacol. 2010;79:955–66.
Richard, R., 2020. A Healthy Inflammatory Response Depends on Neuroendocrine Balance. https://sanescohealth.com/blog/inflammatory-response-and-neuroendocrine-balance/#:~:text=Proinflammatory%20cytokines%20such%20as%20interleukin,to%20a%20reduction%20in%20serotonin.
Rieder CR. Cannabidiol in Parkinson’s disease. Bra J Psychiatry. 2020;42:126–7.
Rizkallah E, Mongeau-Pérusse V, Lamanuzzi L, Stip E, Juteau L-C, Brissette S, Bruneau J, Dubreucq S, Jutras-Aswad D. Cannabidiol effects on cognition in individuals with cocaine use disorder: exploratory results from a randomized controlled trial. Pharmacol Biochem Behav. 2022;216:173376.
Rodríguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M. The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol. 2005;40:2–14.
Run M, Yuan-hui S, Na X. Antioxidant effect of cannabidiol in mice with liver fibrosis. Chin J Pub Health. 2022;38:181–5.
Russo C, Lavorgna M, Nugnes R, Orlo E, Isidori M. Comparative assessment of antimicrobial, antiradical and cytotoxic activities of cannabidiol and its propyl analogue cannabidivarin. Sci Rep. 2021;11:22494.
Russo EB. Cannabis therapeutics and the future of neurology. Front Integr Neurosci. 2018;12:51.
Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005;30:1037–43.
Sacerdote P, Martucci C, Vaccani A, Bariselli F, Panerai A, Colombo A, Parolaro D, Massi P. The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro. J Neuroimmunol. 2005;159:97–105.
Sagredo O, Ramos JA, Decio A, Mechoulam R, Fernández-Ruiz J. Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur J Neurosci. 2007;26:843–51.
Sales AJ, Fogaça MV, Sartim AG, Pereira VS, Wegener G, Guimarães FS, Joca SR. Cannabidiol induces rapid and sustained antidepressant-like effects through increased BDNF signaling and synaptogenesis in the prefrontal cortex. Mol Neurobiol. 2019;56:1070–81.
Salimi H, Klein RS. Disruption of the Blood-Brain Barrier During Neuroinflammatory and Neuroinfectious Diseases. In: Mitoma H, Manto M, editors. Neuroimmune Diseases. Contemporary Clinical Neuroscience. 2019. p. 195–234.
Sauer AV, Hernandez RJ, Fumagalli F, Bianchi V, Poliani PL, Dallatomasina C, Riboni E, Politi LS, Tabucchi A, Carlucci F. Alterations in the brain adenosine metabolism cause behavioral and neurological impairment in ADA-deficient mice and patients. Sci Rep. 2017;7:1–13.
Schiavon AP, Soares LM, Bonato JM, Milani H, Guimarães FS, Weffort de Oliveira RM. Protective effects of cannabidiol against hippocampal cell death and cognitive impairment induced by bilateral common carotid artery occlusion in mice. Neurotox Res. 2014;26:307–16.
Seltzer ES, Watters AK, MacKenzie D Jr, Granat LM, Zhang D. Cannabidiol (CBD) as a promising anti-cancer drug. Cancers (basel). 2020;12:3203.
Shannon S, Lewis N, Lee H, Hughes S. Cannabidiol in anxiety and sleep: a large case series. Permanente J. 2019;23:18.
Shannon S, Opila-Lehman J. Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: a case report. Perm J. 2016;20:16.
Shoval G, Shbiro L, Hershkovitz L, Hazut N, Zalsman G, Mechoulam R, Weller A. Prohedonic effect of cannabidiol in a rat model of depression. Neuropsychobiology. 2016;73:123–9.
Soloey-Nilsen H, Nygaard-Odeh K, Kristiansen MG, Brekke OL, Mollnes TE, Reitan SK, Oiesvold T. Association between brain-derived neurotropic factor (BDNF), high-sensitivity C-reactive protein (hs-CRP) and psychiatric symptoms in medicated and unmedicated patients. BMC Psychiatry. 2022;22:1–7.
Stahl V, Vasudevan K. Comparison of efficacy of cannabinoids versus commercial oral care products in reducing bacterial content from dental plaque: a preliminary observation. Cureus. 2020;12:e6809.
Stence N, Waite M, Dailey ME. Dynamics of microglial activation: a confocal time-lapse analysis in hippocampal slices. Glia. 2001;33:256–66.
Straiker A, Dvorakova M, Zimmowitch A, Mackie K. Cannabidiol inhibits endocannabinoid signaling in autaptic hippocampal neurons. Mol Pharmacol. 2018;94:743–8.
Szaflarski JP, Bebin EM, Comi AM, Patel AD, Joshi C, Checketts D, Beal JC, Laux LC, De Boer LM, Wong MH. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: expanded access program results. Epilepsia. 2018;59:1540–8.
Thomas A, Baillie G, Phillips A, Razdan R, Ross RA, Pertwee R. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol. 2007;150:613–23.
Vallée A, Lecarpentier Y, Guillevin R, Vallée J-N. Effects of cannabidiol interactions with Wnt/β-catenin pathway and PPARγ on oxidative stress and neuroinflammation in Alzheimer’s disease. AcBBS. 2017;49:853–66.
Valvassori SS, Elias G, de Souza B, Petronilho F, Dal-Pizzol F, Kapczinski F, Trzesniak C, Tumas V, Dursun S, Nisihara Chagas MH. Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychopharm. 2011;25:274–80.
van Bergen E, Monnikhof M, Lafeber F, Schutgens R, Mastbergen S, van Vulpen L. The fear for adverse bleeding and cardiovascular events in hemophilia patients using (non-) selective non-steroidal anti-inflammatory drugs: a systematic review reporting on safety. Blood Rev. 2022;56:100987.
Vaseghi S, Arjmandi-Rad S, Eskandari M, Ebrahimnejad M, Kholghi G, Zarrindast M-R. Modulating role of serotonergic signaling in sleep and memory. Pharmacol Rep. 2022;74:1–26.
Victor TR, Hage Z, Tsirka SE. Prophylactic administration of cannabidiol reduces microglial inflammatory response to kainate-induced seizures and neurogenesis. Neuroscience. 2022;500:1–11.
Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil. 2003;17:21–9.
Welty TE, Luebke A, Gidal BE. Cannabidiol: promise and pitfalls: Cannabidiol: promise and pitfalls. Epilepsy Curr. 2014;14:250–2.
Wheless JW, Dlugos D, Miller I, Oh DA, Parikh N, Phillips S, Renfroe JB, Roberts CM, Saeed I, Sparagana SP. Pharmacokinetics and tolerability of multiple doses of pharmaceutical-grade synthetic cannabidiol in pediatric patients with treatment-resistant epilepsy. CNS Drugs. 2019;33:593–604.
White CM. A review of human studies assessing cannabidiol’s (CBD) therapeutic actions and potential. J Clin Pharm. 2019;59:923–34.
Winstone, J., Shafique, H., Clemmer, M.E., Mackie, K., Wager-Miller, J. Effects of Tetrahydrocannabinol and Cannabidiol on Brain-Derived Neurotrophic Factor and Tropomyosin Receptor Kinase B Expression in the Adolescent Hippocampus. Cannabis and Cannabinoid Research. 2022 https://doi.org/10.1089/can.2021.0025
Wójcik P, Gęgotek A, Žarković N, Skrzydlewska E. Disease-dependent antiapoptotic effects of cannabidiol for keratinocytes observed upon UV irradiation. Int J Mol Sci. 2021;22:9956.
Zanelati T, Biojone C, Moreira F, Guimarães FS, Joca SRL. Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol. 2010;159:122–8.
Zhang Y, Dai Y, Wen J, Zhang W, Grenz A, Sun H, Tao L, Lu G, Alexander DC, Milburn MV. Detrimental effects of adenosine signaling in sickle cell disease. Nat Med. 2011;17:79–86.
Zhang Y, Xia Y. Adenosine signaling in normal and sickle erythrocytes and beyond. Microb Infect. 2012;14:863–73.
Zhao J, Gao X, Zhao L, Wang Y, Zhang J, Liu S. Effects of Cannabidiol on Parkinson’s disease in a transgenic mouse model by gut-brain metabolic analysis. Evid-Based Complement Altern Med. 2022;2022:1525113.
Zieba J, Sinclair D, Sebree T, Bonn-Miller M, Gutterman D, Siegel S, Karl T. Cannabidiol (CBD) reduces anxiety-related behavior in mice via an FMRP-independent mechanism. Pharmacol Biochem Behav. 2019;181:93–100.
Zimmerman JJ, von Saint André-von Arnim A, McLaughlin J. Cellular respiration. Ped Crit Care. 2011;4:1058–72.
Zuardi AW, Cosme R, Graeff FG, Guimarães F. Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharm. 1993;7:82–8.
